BGM
CMPX icon

Burkehill Global Management’s Compass Therapeutics CMPX Stock Holding History

Burkehill Global Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Hold
700,000
– – 0.06% 138
2026
Q1 		$3.7M Hold
700,000
– – 0.18% 92
2025
Q4 		$3.76M Hold
700,000
– – 0.25% 90
2025
Q3 		$2.45M Buy
+700,000
New +$2.21M 0.14% 111

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Burkehill Global Management's CMPX Position: Q2 2026 in Review

Burkehill Global Management held its Compass Therapeutics (CMPX) position steady in Q2 2026 at 700,000 shares worth $1.53M. The position accounts for 0.06% of the portfolio, ranked #138.

Burkehill Global Management first reported a position in CMPX in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.76M in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Burkehill Global Management held 700,000 shares of Compass Therapeutics worth $1.53M as of Q2 2026.
  • Burkehill Global Management left its Compass Therapeutics share count unchanged in Q2 2026.
  • Compass Therapeutics made up 0.06% of Burkehill Global Management's portfolio in Q2 2026, its #138 holding.
  • Burkehill Global Management first reported a position in Compass Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Burkehill Global Management's Compass Therapeutics position peaked at $3.76M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.